Cargando…
Oncolytic Viruses: Therapeutics With an Identity Crisis
Oncolytic viruses (OV) are replicating viral therapeutics for the treatment of cancer and have been in laboratory development for about twenty years. Recently, the FDA approved Imlygic, a herpes virus based therapeutic for the treatment of melanoma and thus OVs have entered a new era where they are...
Autores principales: | Breitbach, Caroline J., Lichty, Brian D., Bell, John C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972563/ https://www.ncbi.nlm.nih.gov/pubmed/27407036 http://dx.doi.org/10.1016/j.ebiom.2016.06.046 |
Ejemplares similares
-
Development and applications of oncolytic Maraba virus vaccines
por: Pol, Jonathan G, et al.
Publicado: (2018) -
The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)
por: Breitbach, Caroline J, et al.
Publicado: (2015) -
Oncolytic viruses as therapeutic cancer vaccines
por: Bartlett, David L, et al.
Publicado: (2013) -
Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses
por: Ungerechts, Guy, et al.
Publicado: (2016) -
Cell carriers for oncolytic viruses: current challenges and future directions
por: Roy, Dominic G, et al.
Publicado: (2013)